{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:42:31Z","timestamp":1770482551330,"version":"3.49.0"},"reference-count":20,"publisher":"Hindawi Limited","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1803,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1529-8019.2010.01357.x","type":"journal-article","created":{"date-parts":[[2010,9,24]],"date-time":"2010-09-24T19:52:35Z","timestamp":1285357955000},"page":"541-543","source":"Crossref","is-referenced-by-count":9,"title":["THERAPEUTIC HOTLINE: Infliximab for treatment of resistant pyoderma gangrenosum associated with ulcerative colitis and psoriasis. A case report"],"prefix":"10.1155","volume":"23","author":[{"given":"Francesco","family":"Baglieri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Scuderi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2010,9,24]]},"reference":[{"key":"10.1111\/j.1529-8019.2010.01357.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/archderm.1930.01440160053009","article-title":"Pyoderma (ecthyma) gangrenosum: clinical and experimental observations in five cases occurring in adults","volume":"22","author":"Brunsting","year":"1930","journal-title":"Arch Dermatol Syph"},{"key":"10.1111\/j.1529-8019.2010.01357.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1034\/j.1600-0560.2003.00024.x","article-title":"Pyoderma gangrenosum: a review","volume":"30","author":"Crowson","year":"2003","journal-title":"J Cutan Pathol"},{"key":"10.1111\/j.1529-8019.2010.01357.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1046\/j.1365-4362.2002.01373_1.x","article-title":"Pathergic pyoderma gangrenosum in a venous ulcer","volume":"41","author":"Rosina","year":"2002","journal-title":"Int J Dermatol"},{"key":"10.1111\/j.1529-8019.2010.01357.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00105-008-1654-4","article-title":"Psoriasis vulgaris as a trigger for a superficial multilocular pyoderma gangrenosum?","volume":"60","author":"Klode","year":"2009","journal-title":"Hautarzt"},{"key":"10.1111\/j.1529-8019.2010.01357.x-BIB5|cit5","first-page":"88","article-title":"Clinical manifestations of pyoderma gangrenosum associated with inflammatory bowel disease","volume":"6","author":"Menachem","year":"2004","journal-title":"Isr Med Assoc J"},{"key":"10.1111\/j.1529-8019.2010.01357.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1080\/09546630410031909","article-title":"Review of 26 cases of classical pyoderma gangrenosum: clinical and therapeutic features","volume":"15","author":"Vidal","year":"2004","journal-title":"J Dermatolog Treat"},{"key":"10.1111\/j.1529-8019.2010.01357.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaad.2004.10.006","article-title":"Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients","volume":"53","author":"Reichrath","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2010.01357.x-BIB8|cit8","first-page":"930","article-title":"Improvement of pyoderma gangrenosum and psoriasis associated with Crohn's disease with anti-TNF-\u03b1 monoclonal antibody","volume":"137","author":"Tan","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2010.01357.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2133.2005.06812.x","article-title":"Severe recalcitrant pyoderma gangrenosum treated with infliximab","volume":"153","author":"Kaur","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2010.01357.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomized, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"key":"10.1111\/j.1529-8019.2010.01357.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2165\/00128071-200304090-00002","article-title":"Optimal treatment of pyoderma gangrenosum","volume":"4","author":"Gettler","year":"2003","journal-title":"Am J Clin Dermatol"},{"key":"10.1111\/j.1529-8019.2010.01357.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1572-0241.2001.03756.x","article-title":"The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study","volume":"96","author":"Bernstein","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1529-8019.2010.01357.x-BIB13|cit13","first-page":"768","article-title":"Ulcerative colitis: analyses of 116 cases \/do extraintestinal manifestations effect time to catch remission?","volume":"51","author":"Ozdil","year":"2004","journal-title":"Hepatogastroenterology"},{"key":"10.1111\/j.1529-8019.2010.01357.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1046\/j.1523-1747.1998.00311.x","article-title":"Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum","volume":"111","author":"Adachi","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1529-8019.2010.01357.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/labinvest.3780064","article-title":"Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers and leads to ulcer formation in human skin xenografts","volume":"80","author":"Oka","year":"2000","journal-title":"Lab Invest"},{"key":"10.1111\/j.1529-8019.2010.01357.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1365-4632.2007.03286.x","article-title":"Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series","volume":"46","author":"Charles","year":"2007","journal-title":"Int J Dermatol"},{"key":"10.1111\/j.1529-8019.2010.01357.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3109\/09546630902936778","article-title":"Non-psoriatic dermatologic uses of monoclonal antibody therapy","volume":"20","author":"Sockolov","year":"2009","journal-title":"J Dermatolog Treat"},{"key":"10.1111\/j.1529-8019.2010.01357.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000111515","article-title":"Treatment of idiopathic pyoderma gangrenosum with infliximab: induction dosing regimen or on-demand therapy?","volume":"216","author":"Adijen","year":"2008","journal-title":"Dermatology"},{"key":"10.1111\/j.1529-8019.2010.01357.x-BIB19|cit19","first-page":"163","article-title":"Pyoderma gangrenosum treated with infliximab in inactive ulcerative colitis","volume":"216","author":"Ermis","year":"2008","journal-title":"Dermatology"},{"key":"10.1111\/j.1529-8019.2010.01357.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/keh483","article-title":"Anti-TNF-\u03b1 therapies: they are all the same (aren't they?)","volume":"44","author":"Mpofu","year":"2005","journal-title":"Rheumatology (Oxford)"}],"container-title":["Dermatologic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1529-8019.2010.01357.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1529-8019.2010.01357.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T17:58:09Z","timestamp":1671818289000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1529-8019.2010.01357.x"}},"subtitle":["Infliximab for treatment of resistant PG"],"short-title":[],"issued":{"date-parts":[[2010,9,24]]},"references-count":20,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.1111\/j.1529-8019.2010.01357.x","relation":{},"ISSN":["1396-0296"],"issn-type":[{"value":"1396-0296","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9,24]]}}}